Estrella Immunopharma, Inc. (ESLA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US2975841048
Estrella Immunopharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -13.06 m USD |
| EBIT | -13.06 m USD |
| Net income | -13.06 m USD |
| Diluted EPS – continuing operations | -0.35 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
More stocks
- Starco Brands, Inc. (STCB)
- Beam Global (BEEM)
- Cosmos Health Inc. (COSM)
- SANUWAVE Health, Inc. (SNWV)
- Seres Therapeutics, Inc. (MCRB)
- Vivid Seats Inc. (SEAT)
- SBI Investment KOREA Co. Ltd (019550.KQ)
- PACIFIC HEALTH CARE ORGANIZATION INC (PFHO)
- ARTS WAY MANUFACTURING CO INC (ARTW)
- QUOTEMEDIA INC (QMCI)
- Sphere 3D Corp. (ANY)
- Pacific Sports Exchange Inc. (PSPX)
Not investment advice. All data without warranty, price as of 18.11.2026. Details in the risk notice.